Methadone for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  Nicholson, Alexander B ^a   Watson, Graeme R ^a   Derry, Sheena ^b   Wiffen, Philip J ^b  

^a SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; FENTANYL; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CANCER PAIN; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NAUSEA; PAIN INTENSITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT REFUSAL; VOMITING; XEROSTOMIA; ADULT; AGED; COMPLICATION; MIDDLE AGED; NEOPLASM; PAIN; PAIN MEASUREMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; HUMANS; METHADONE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85012031552     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003971.pub4     Document Type: Review

References (47)

1. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clinical Pharmacololgy and Therapeutics 1967;8(3):415-26. [2814745; PUBMED: 5338385]
2. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology 2004;22(1):185-92. [2814747; DOI: 10.1200/JCO.2004.03.172]
3. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home. Journal of Clinical Oncology 1998;16(11):3656-61. [2814749; PUBMED: 9817288]
4. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain 2008;12:1040-6. [2814751; DOI: 10.1016/j.ejpain.2008.01.013]
5. Twycross R. A comparison of diamorphine with cocaine and methadone (letter). British Journal of Clinical Practice 1977;4:691-93. [2814753; PUBMED: 69292]
6. Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management 1986;1(4):203-7. [2814755; DOI: 10.1016/S0885-3924(86)80042-2]
7. Cubero DIG, del Giglio A. Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. Supportive Care in Cancer 2010;18(2):235-42. [2814757; DOI: 10.1007/s00520-009-0649-8]
8. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. American Journal of Medicine 1984;77(1A):78-83. [2814759; DOI: 10.1016/S0002-9343(84)80023-6]
9. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986;25(3):297-312. [2814761; DOI: 10.1016/0304-3959(86)90234-4]
10. Grochow L, Sheidler V, Grossman S, Green L, Enterline J. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomised, double blind study. Pain 1989;38(2):151-7. [2814763; DOI: 10.1016/0304-3959(89)90233-9]
11. Lauretti GR, Rizzo CC, Mattos AL, Rodrigues SW. Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. British Journal of Cancer 2013;108(2):259-64. [2814765; DOI: 10.1038/bjc.2012.593]
12. Matts SGF, Swan CHF, Wharton BA. Double blind trial of dextromoramide, methadone and pethidine in the treatment of severe pain. Postgraduate Medical Journal 1964;40:103-5. [2814767; PUBMED: 14122903]
13. Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S. How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. European Journal of Cancer 2011;47(16):2463-70. [2814769; DOI: 10.1016/j.ejca.2011.06.047]
14. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliative Medicine 2003; Vol. 17, issue 7:576-87. [2814771; PUBMED: 14594148]
15. Prommer E (lead investigator). Methadone versus morphine for cancer related pain. clinicaltrials.gov/ct2/show/NCT00573937 (accessed 21 April 2016) 2016. [2814773; CTG: NCT00573937]
16. Fisch MJ (lead investigator). Methadone, morphine, or oxycodone in treating pain in patients with cancer. clinicaltrials.gov/ct2/show/NCT00726830 (accessed 21 April 2016) 2012. [2814775; CTG: NCT00726830]
17. Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Practice 2014;14(1):32-42. [2814777; DOI: 10.1111/papr.12045]
18. Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991;45(2):141-3. [DOI: 10.1016/0304-3959(91)90179-2]
19. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. Journal of Palliative Medicine 2002;5(1):127-38. [DOI: 10.1089/10966210252785097]
20. Cruciani RA. Methadone: to ECG or not to ECG.... That is still the question. Journal of Pain and Symptom Management 2008;36(5):545-52. [DOI: 10.1016/j.jpainsymman.2007.11.003]
21. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Supportive Care in Cancer 2001;9(2):73-83. [DOI: 10.1007/s005200000180]
22. Anon . More care, less pathway. A review of the Liverpool Care Pathway. Report by Baroness Julia Neuberger (Chair), available at www.gov.uk/government/uploads/system/uploads/attachment_data/file/212450/Liverpool_Care_Pathway.pdf (accessed 21 April 2016).
23. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;51(2):137-47. [DOI: 10.1016/0304-3959(93)90125-9]
24. Gannon C. The use of methadone in the care of the dying. European Journal of Palliative Care 1997;4(5):152-8.
25. Good P, Afsharimani B, Movva R, Haywood A, Khan S Hardy J. Therapeutic challenges in cancer pain management: a systematic review of methadone. Journal of Pain and Palliative Care Pharmacotherapy 2014;28(3):197-205. [DOI: 10.3109/15360288.2014.938883]
26. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters 1997;223(1):5-8.
27. Graner KM, Rolim GS, Moraes AB, Padovani CR, Lopes MA, Santos-Silva AR, et al. Feelings, perceptions, and expectations of patients during the process of oral cancer diagnosis. Support Care Cancer 2016;24:2323-32. [DOI: 10.1007/s00520-015-3030-0]
28. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
29. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
30. Hanks GWC, Cherny N. Opioid analgesic therapy. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 1998:331-51.
31. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
32. Ma H, Liu Y, Huang L, Zeng XT, Jin SH, Yue GJ, et al. The adverse events of oxycodone in cancer-related pain: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95(15):e3341. [DOI: 10.1097/MD.0000000000003341]
33. Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. Journal of Pain and Symptom Management 1999;18(1):49-52. [DOI: 10.1016/S0885-3924(99)00020-2]
34. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]
35. Payne R, Gonzales GR. Pathophysiology of pain in cancer and other terminal diseases. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 1998:299-310.
36. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
37. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70(2-3):109-15. [DOI: 10.1016/S0304-3959(96)03286-1]
38. Twycross R, Wilcock A, Thorpe S. Palliative Care Formulary. Oxford: Radcliffe Medical Press, 1998.
39. Twycross R, Wilcock A (Eds). PCF5 Palliative Care Formulary. Fifth. Nottingham: palliativedrugs.com Ltd, 2014. [ISBN: 978-0-9552547-9-6]
40. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007;132:312-20.
41. van den Beuken-van Everdingen MH, Geurts JW, Patijn J. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain. Journal of Opioid Management 2013;9(4):263-7. [DOI: 10.5055/jom.2013.0167]
42. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59(4):850-6. [PUBMED: 3802043]
43. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Medicine 2008;9(3):315-44. [DOI: 10.1111/j.1526-4637.2006.00289.x]
44. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2]
45. Nicholson A, Davies A, Reid C. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2002, Issue 11. [DOI: 10.1002/14651858.CD003971]
46. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003971.pub2]
47. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2007, Issue 10. [DOI: 10.1002/14651858.CD003971.pub3]